Biocytogen Pharmaceuticals (Beijing) Management
Management criteria checks 4/4
Biocytogen Pharmaceuticals (Beijing)'s CEO is Yuelei Shen, appointed in Nov 2009, has a tenure of 15.08 years. total yearly compensation is CN¥2.06M, comprised of 86.6% salary and 13.4% bonuses, including company stock and options. directly owns 6.61% of the company’s shares, worth HK$221.72M. The average tenure of the management team and the board of directors is 5.4 years and 4.7 years respectively.
Key information
Yuelei Shen
Chief executive officer
CN¥2.1m
Total compensation
| CEO salary percentage | 86.6% |
| CEO tenure | 15.1yrs |
| CEO ownership | 6.6% |
| Management average tenure | 5.4yrs |
| Board average tenure | 4.7yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥244m |
| Mar 31 2024 | n/a | n/a | -CN¥313m |
| Dec 31 2023 | CN¥2m | CN¥2m | -CN¥383m |
| Sep 30 2023 | n/a | n/a | -CN¥451m |
| Jun 30 2023 | n/a | n/a | -CN¥519m |
| Mar 31 2023 | n/a | n/a | -CN¥561m |
| Dec 31 2022 | CN¥3m | CN¥2m | -CN¥602m |
| Sep 30 2022 | n/a | n/a | -CN¥585m |
| Jun 30 2022 | n/a | n/a | -CN¥569m |
| Mar 31 2022 | n/a | n/a | -CN¥557m |
| Dec 31 2021 | CN¥6m | CN¥2m | -CN¥546m |
| Dec 31 2020 | CN¥120m | CN¥2m | -CN¥217m |
Compensation vs Market: Yuelei's total compensation ($USD281.99K) is about average for companies of similar size in the Hong Kong market ($USD384.84K).
Compensation vs Earnings: Yuelei's compensation has been consistent with company performance over the past year.
CEO
Yuelei Shen (54 yo)
15.1yrs
Tenure
CN¥2,058,000
Compensation
Dr. Yuelei Shen, Ph D., is the Founder and Chief Executive Officer of Eucure (Beijing) Biopharma Co., Ltd., and its General Manager and Executive Director since August 2021. Dr. Shen is Chairman, President...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 15.1yrs | CN¥2.06m | 6.61% HK$ 221.7m | |
| Executive Director | 15.1yrs | no data | 7.26% HK$ 243.6m | |
| Senior Operation Director of Animal Center & Executive Director | 5.4yrs | CN¥1.01m | no data | |
| CFO & Deputy GM | 4.6yrs | no data | no data | |
| Chief Scientific Officer & Deputy GM | 4.9yrs | no data | no data | |
| VP of Marketing & Deputy GM | 9.5yrs | no data | no data | |
| Director of Human Resources & Supervisor | 4.3yrs | no data | no data | |
| Chairman of the Supervisory Committee & Director of the President’s Office | 9.4yrs | no data | no data | |
| Deputy GM & CEO of Biocytogen Boston Corp. | 6.8yrs | no data | no data | |
| Deputy GM | 3.4yrs | no data | no data | |
| Joint Company Secretary | 2.3yrs | no data | no data |
5.4yrs
Average Tenure
48yo
Average Age
Experienced Management: 2315's management team is seasoned and experienced (5.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 15.1yrs | CN¥2.06m | 6.61% HK$ 221.7m | |
| Executive Director | 15.1yrs | no data | 7.26% HK$ 243.6m | |
| Senior Operation Director of Animal Center & Executive Director | 5.4yrs | CN¥1.01m | no data | |
| Director of Human Resources & Supervisor | 4yrs | no data | no data | |
| Chairman of the Supervisory Committee & Director of the President’s Office | 5.4yrs | no data | no data | |
| Independent Non-Executive Director | 3.4yrs | CN¥120.00k | no data | |
| Non-Executive Director | 2.1yrs | no data | no data | |
| Non-Executive Director | 6.8yrs | no data | no data | |
| Non-Executive Director | 9.3yrs | no data | no data | |
| Independent Non-Executive Director | 4yrs | CN¥120.00k | no data | |
| Independent Non-Executive Director | 4yrs | CN¥120.00k | no data | |
| Supervisor | 2.1yrs | no data | no data |
4.7yrs
Average Tenure
52yo
Average Age
Experienced Board: 2315's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 13:58 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | CMB International Securities Limited |
| Ziyi Chen | Goldman Sachs |
| Kehan Meng | Haitong International Research Limited |